PS 873266

Drug Profile

PS 873266

Alternative Names: PS873266

Latest Information Update: 11 Apr 2011

Price : $50

At a glance

  • Originator Celgene Corporation; Pharmacopeia Drug Discovery
  • Developer Celgene Corporation
  • Class Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 11 Apr 2011 Phase-I development is ongoing in USA
  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
  • 05 Mar 2008 Phase-I clinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top